JP Morgan Chase’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-24,721
| Closed | -$65.8K | – | 7892 |
|
|
2024
Q1 | $65.8K | Buy |
24,721
+24,658
| +39,140% | +$61K | ﹤0.01% | 5837 |
|
|
2023
Q4 | $149 | Sell |
63
-8,811
| -99% | -$15.6K | ﹤0.01% | 7082 |
|
|
2023
Q3 | $12.4K | Buy |
8,874
+7,338
| +478% | +$17.6K | ﹤0.01% | 6203 |
|
|
2023
Q2 | $4.65K | Sell |
1,536
-22,344
| -94% | -$86.1K | ﹤0.01% | 6186 |
|
|
2023
Q1 | $149K | Buy |
23,880
+5,962
| +33% | +$36.3K | ﹤0.01% | 5239 |
|
|
2022
Q4 | $109K | Sell |
17,918
-1,156
| -6% | -$9.41K | ﹤0.01% | 5324 |
|
|
2022
Q3 | $228K | Buy |
19,074
+1,567
| +9% | +$20.5K | ﹤0.01% | 4886 |
|
|
2022
Q2 | $221K | Sell |
17,507
-4,363
| -20% | -$40.6K | ﹤0.01% | 5026 |
|
|
2022
Q1 | $246K | Buy |
21,870
+3,756
| +21% | +$41.3K | ﹤0.01% | 5085 |
|
|
2021
Q4 | $321K | Buy |
18,114
+4,696
| +35% | +$99K | ﹤0.01% | 5091 |
|
|
2021
Q3 | $309K | Buy |
13,418
+5,271
| +65% | +$115K | ﹤0.01% | 5006 |
|
|
2021
Q2 | $189K | Buy |
8,147
+3,079
| +61% | +$78.3K | ﹤0.01% | 5276 |
|
|
2021
Q1 | $158K | Buy |
+5,068
| New | +$177K | ﹤0.01% | 5237 |
|
JP Morgan Chase's KNTE Position: Q2 2024 in Review
JP Morgan Chase sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 24,721 shares — an estimated $65.8K sold.
JP Morgan Chase first reported a position in KNTE in Q1 2021 and held it in 13 quarters. The position peaked at $321K in Q4 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- JP Morgan Chase reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- JP Morgan Chase sold 24,721 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $65.8K.
- JP Morgan Chase first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- JP Morgan Chase's Kinnate Biopharma Inc. Common Stock position peaked at $321K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.